Zhitong Financial APP News, Maibo Pharmaceutical-B (02181) released its interim results for the six months ended June 30, 2023. The group achieved operating income of 44.02 million yuan (the same as below), an increase of 52.6% over the same period last year; R & D expenditure of 59.527 million yuan, down 23.7% from the same period last year; loss attributable to company owners was 99.999 million yuan, down 14.4% from the same period last year; loss per share was 0.02 yuan.
The company already has efficient R & D capability, extensive and advanced preparation technology and low-cost drug production capacity, enabling the company to provide high-quality and reasonably priced innovative biopharmaceutical products to patients in China and other emerging markets. In the company's product pipeline, CMAB008 and CMAB007 have been listed and commercialized, CMAB009 has submitted an NDA application, is undergoing on-site verification of research and development, and is about to be approved for listing; CMAB807 is about to apply for NDA. The company also has a number of core technology patents, including antibody engineering and humanization technology, high expression vector construction technology, efficient cloning and screening technology, and proprietary research and development of animal models. The company's R & D activities are carried out by three core teams: basic R & D, clinical trials and GMP-compliant product preparation. The operation, design and construction requirements of the three core teams are supported by the auxiliary engineering team. The company's R & D team is composed of professionals with rich industry experience in biological agent research and development and valuable work experience in global pharmaceutical companies. The company's R & D team employees have a solid academic background in immunology, molecular biology, oncology or monoclonal antibody research and development in leading institutions.